Unfortunately, for those prescribed GLP-1 medications for weight loss or diabetes management, like Ozempic, an injection is the only option for nearly all versions of this drug
[25] Cancer [edit] In response to a report of precancerous changes in the pancreases of rats and organ donors treated with the DPP-4 inhibitor sitagliptin, [26] [27] the US FDA and the European Medicines Agency each undertook independent reviews of all clinical and preclinical data related to the possible association of DPP-4 inhibitors with pancreatic cancer
At 6 or 12 months, depending on the progress made, the doctor might recommend keeping the same dose if there is no slowing of the weight loss, or if there is no further improvement for some time, so you may be switched to a higher dose
However, these are general guidelines, not automatic qualifiers
in the New England Journal of Medicine (2023), enrolled 338 adults with obesity (BMI 30 or higher) or overweight (BMI 2730) with at least one weight-related condition
PMCID: PMC7213778